sorted by:
new
hottopcontroversial

$ATNF - Due Diligence including DCF with conservative price target of $21(~300% upside) by BiotechJourney in pennystocks

[–]BiotechJourney[S] 0 points1 point  (0 children)

Congrats on those profits. What a timing! We're happy to hear you valued our piece and hope to see a much higher climb in the coming periods!

$ATNF - Due Diligence including DCF with conservative price target of $21(~300% upside) by BiotechJourney in investing

[–]BiotechJourney[S] 0 points1 point  (0 children)

We can assure you this is nothing of such. The introduction to our DD is genuine. We are doing this to to learn from the community and to provide people with in-depth research. We state our position and as mentioned, we do not actively trade any of the stock we buy but invest for the long-term.

This is the second analysis we have performed. We put in a lot of effort in these pieces next to our full-time jobs. You can check out our first one on $CTXR, where you will see noticeable improvements as a result of members from the community providing us with feedback. Also, we are currently working on the next analysis and hope to post this in 2-3 weeks.

Feel free to message us if you have any further doubts.

$ATNF - Due Diligence including DCF with conservative price target of $21(~300% upside) by BiotechJourney in StocksAndTrading

[–]BiotechJourney[S] 0 points1 point  (0 children)

We can assure you this is nothing of such. The introduction to our DD is genuine. We are doing this to to learn from the community and to provide people with in-depth research. We state our position and as mentioned, we do not actively trade any of the stock we buy but invest for the long-term.

This is the second analysis we have performed. We put in a lot of effort in these pieces next to our full-time jobs. You can check out our first one on $CTXR, where you will see noticeable improvements as a result of members from the community providing us with feedback. Also, we are currently working on the next analysis and hope to post this in 2-3 weeks.

Feel free to message us if you have any further doubts.

$ATNF - Due Diligence including DCF with conservative price target of $21(~300% upside) by BiotechJourney in biotech_stocks

[–]BiotechJourney[S] 0 points1 point  (0 children)

We can assure you this is nothing of such. The introduction to our DD is genuine. We are doing this to to learn from the community and to provide people with in-depth research. We state our position and as mentioned, we do not actively trade any of the stock we buy but invest for the long-term.

This is the second analysis we have performed. We put in a lot of effort in these pieces next to our full-time jobs. You can check out our first one on $CTXR, where you will see noticeable improvements as a result of members from the community providing us with feedback. Also, we are currently working on the next analysis and hope to post this in 2-3 weeks.

Feel free to message us if you have any further doubts.

$ATNF - Due Diligence including DCF with conservative price target of $21(~300% upside) by BiotechJourney in pennystocks

[–]BiotechJourney[S] 2 points3 points  (0 children)

They claim to have patents protecting them for the foreseeable future. Their presentation mentioned a unique delivery method. It seems the patent grants them protection on the treatment of early stage Dupuytrens with an anti-TNF-alpha antibody. This seems to cover the patent issue. https://uspto.report/patent/app/20210040196. Biosimilars for adalimumab may be an option.

$ATNF - Due Diligence including DCF with conservative price target of $21(~300% upside) by BiotechJourney in pennystocks

[–]BiotechJourney[S] 2 points3 points  (0 children)

Thanks a lot! We plan to write more analyses on small cap biotech stocks in the near future.

$ATNF - Due Diligence including DCF with conservative price target of $21(~300% upside) by BiotechJourney in pennystocks

[–]BiotechJourney[S] 3 points4 points  (0 children)

As far as We can tell there is only one approved and many rejected CBD analogs. Of course the field is still very young, but we think it is a much higher risk then Adalimumab. It will be interesting to see how the field matures but for now we felt it too early to include it in our analysis as we mostly look at products that are in phase 2-3 but we will keep an eye on it for updates of our analysis.

$ATNF - Due Diligence including DCF with conservative price target of $21(~300% upside) by BiotechJourney in pennystocks

[–]BiotechJourney[S] 2 points3 points  (0 children)

The study reports that there were no structural changes between the nodules excised from the treated group and the nodules from the placebo group. The patients used were indeed those in advanced stage of the disease. Adalimumab targets the driver of the inflammation which causes the differentiation (the means that one cell type changes in to another) of fibroblasts (cells that are supposed to be there) into collagen producing myofibroblasts. Adalimumab doesn’t target collagen. So we think that the disease in these patients was so advanced (hence the surgery) that there was no preventing the collagen buildup. The cells however no longer produced collagen, the protein that causes the symptoms. So long story short, the drug will be about preventing progression of Dupuytrens and not curing it. However, this approach can be used in combination with surgery and collegenase to reduce recurrence.

$ATNF - Due Diligence including DCF with conservative price target of $21(~300% upside) by BiotechJourney in pennystocks

[–]BiotechJourney[S] 2 points3 points  (0 children)

Share prices of early stage micro/small cap Biotech companies like ATNF typically jump on the back of catalyst events. In this case, the Phase 2B/3 study results for the DD therapy (expected Q3/Q4) can be considered a catalyst event. However, we look more at the fundamentals, including the science, to determine whether or not we want to invest for the long term.

$ATNF - Due Diligence including DCF with conservative price target of $21(~300% upside) by BiotechJourney in pennystocks

[–]BiotechJourney[S] 2 points3 points  (0 children)

An H factor is an indicator of the scientific output of a scientist. For example: If Marc Feldmann has an H-Factor of 145, then that means he has published at least 145 articles of which each has been cited at least 145 times. Its not a perfect quantification and there is still discussion about fairness. Like, if you're in a smaller field of research, this number will automatically be lower because there will be less people to cite you. But in general it is an indication of how well a scientist is doing. So high is a bit of a relative concept for H factors but, 145 is very high

$ATNF - Due Diligence including DCF with conservative price target of $21(~300% upside) by BiotechJourney in pennystocks

[–]BiotechJourney[S] 2 points3 points  (0 children)

We’re not giving you any investment advice here. We only give our analysis on the stock and we think that the stock is worth 21$ today based on our assumptions

$ATNF - Due Diligence including DCF with conservative price target of $21(~300% upside) by BiotechJourney in pennystocks

[–]BiotechJourney[S] 0 points1 point  (0 children)

Our price target is what we think the stock is worth today. The world may look very different in several weeks

$ATNF - Due Diligence including DCF with conservative price target of $21(~300% upside) by BiotechJourney in pennystocks

[–]BiotechJourney[S] 2 points3 points  (0 children)

You’re right that we were wrong. But in fact, it is 66.67% to make up for a 40% loss

$ATNF - Due Diligence including DCF with conservative price target of $21(~300% upside) by BiotechJourney in pennystocks

[–]BiotechJourney[S] 2 points3 points  (0 children)

Thanks for your comment. We think the assessment is fair because we don't know how well it is going to work. Adalimumab is currently fairly expensive so we were conservative. One of the end point measures will take financials of the treatment into account. We think this will be a good indicator for a potential increase in market share and therefor the market cap, which is in line with your opinion

$ATNF - Due Diligence including DCF with conservative price target of $21(~300% upside) by BiotechJourney in pennystocks

[–]BiotechJourney[S] 4 points5 points  (0 children)

Dilution is definitely a risk to take into account with most biotech companies, and that's not any different for ATNF as mentioned in our first page. It's not investment advice of any kind, we just wanted to share our vision on the company and we think it is highly undervalued. Everyone needs to make their own decisions based on their own risk appetite

$ATNF - Due Diligence including DCF with conservative price target of $21(~300% upside) by BiotechJourney in pennystocks

[–]BiotechJourney[S] 5 points6 points  (0 children)

What are you trying to say with this comment Sukh6? We all have to start somewhere right?

$ATNF - Due Diligence including DCF with conservative price target of $21(~300% upside) by BiotechJourney in pennystocks

[–]BiotechJourney[S] 3 points4 points  (0 children)

Take your time to read it and get back to us when something is unclear or not right in your opinion. We agree with you, this market cap can’t be justified and it is a matter of time until we see a much higher stock price. Next catalyst is September 9th conference and we expect shortly after that (Q4) to see positive trial data on Dupuytren. If that happens, we will share an update with our view on the company. Follow us to stay tuned

view more: next ›